EHA Library - The official digital education library of European Hematology Association (EHA)

ESSENTIAL TRHOMBOCYTHEMIA: STUDY OF TREATMENT LINES REQUIRED. EXPERIENCE OF A SINGLE CENTER
Author(s):
Mercedes Berenguer
,
Mercedes Berenguer
Affiliations:
Hematology,Hospital Clínico Universitario Virgen de la Arrixaca,Murcia,Spain
Raúl Pérez López
,
Raúl Pérez López
Affiliations:
Hospital Clínico Universitario Virgen de la Arrixaca,Murcia,Spain
Valentin Cabañas-Perianes
,
Valentin Cabañas-Perianes
Affiliations:
Hospital Clínico Universitario Virgen de la Arrixaca,Murcia,Spain
María Moya-Arnao
,
María Moya-Arnao
Affiliations:
Hospital Clínico Universitario Virgen de la Arrixaca,Murcia,Spain
Nicolás Ortega-López
,
Nicolás Ortega-López
Affiliations:
Internal Medicine,Hospital Clínico Universitario Virgen de la Arrixaca,Murcia,Spain
Eduardo Salido-Fiérrez
,
Eduardo Salido-Fiérrez
Affiliations:
Hospital Clínico Universitario Virgen de la Arrixaca,Murcia,Spain
Amelia Martínez-Marín
,
Amelia Martínez-Marín
Affiliations:
Hospital Clínico Universitario Virgen de la Arrixaca,Murcia,Spain
Elena Fernández-Poveda
,
Elena Fernández-Poveda
Affiliations:
Hospital Clínico Universitario Virgen de la Arrixaca,Murcia,Spain
José María Moraleda-Jiménez
José María Moraleda-Jiménez
Affiliations:
Hospital Clínico Universitario Virgen de la Arrixaca,Murcia,Spain
(Abstract release date: 05/18/17) EHA Library. Berenguer M. 05/18/17; 182747; PB2033
Mercedes Berenguer
Mercedes Berenguer
Contributions
PDF Abstract
Abstract

Abstract: PB2033

Type: Publication Only

Background
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm that shows similar survival prognosis as general population, with a very low rate of transformation to myelofibrosis and acute leukemia.

There are different treatments for these patients with optimal responses at first. For the first line, it is usually threated with hydroxyurea, although in young patients it is usually replaced by anagrelide / interferon.
There are publications of hydroxyurea side effects, especially cutaneous, but there are not many studies about how many lines of treatment are needed to control the disease.

Aims
Study type and lines of treatment needed in patients with ET in a cohort of patients from January 1997 to January 2017.

Methods
We studied patients diagnosed of essential thrombocythemia in one area of the region of Murcia from January, 1997 to January, 2017. Those who started treatment and those who needed change were analyzed, either by resistance or by intolerance.

Results

In our area we have registered a total of 152 patients diagnosed with ET. Of these, 71% (108 patients) have required at least one treatment line.
Table 1 shows the number of treatment lines required for the control of the disease.
As it is shown in the table, more than 20% of treated patients needed a second line and 6,5% required more tan 2 lines.
At last, table 3 shows current treatment of ET patients.
Table 1. Number of line treatmentes required for disease control.
Treatment lines
N (%)
1
76 (70,3)
2
23 (21,2)
3
7 (6,48)
4
1 (0,92)
5
1 (0,92)
Table 2. Drugs used in patients with ET.
Treatment
N
Hydroxiurea
99
Anagrelide
31
Interferon
10
Busulfan
4
Melphalan
1
Danazol
1
Table 3. Current treatment of ET patients
Current treatment
N
No treatment
34 (29 never treated, 5 no currently)
in treatment
108
Hydroxyurea
76
Anagrelide
22
INF
6
Busulfan
1
Danazol
1
Hydroxyurea + Anagrelide
2

Conclusion
This study highlights that, although ET has a very good prognosis, there is a significant percentage of patients that will need a change of treatment, either because of resistence or intolerance.

Session topic: 16. Myeloproliferative neoplasms - Clinical

Keyword(s): Treatment, Essential Thrombocytemia

Abstract: PB2033

Type: Publication Only

Background
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm that shows similar survival prognosis as general population, with a very low rate of transformation to myelofibrosis and acute leukemia.

There are different treatments for these patients with optimal responses at first. For the first line, it is usually threated with hydroxyurea, although in young patients it is usually replaced by anagrelide / interferon.
There are publications of hydroxyurea side effects, especially cutaneous, but there are not many studies about how many lines of treatment are needed to control the disease.

Aims
Study type and lines of treatment needed in patients with ET in a cohort of patients from January 1997 to January 2017.

Methods
We studied patients diagnosed of essential thrombocythemia in one area of the region of Murcia from January, 1997 to January, 2017. Those who started treatment and those who needed change were analyzed, either by resistance or by intolerance.

Results

In our area we have registered a total of 152 patients diagnosed with ET. Of these, 71% (108 patients) have required at least one treatment line.
Table 1 shows the number of treatment lines required for the control of the disease.
As it is shown in the table, more than 20% of treated patients needed a second line and 6,5% required more tan 2 lines.
At last, table 3 shows current treatment of ET patients.
Table 1. Number of line treatmentes required for disease control.
Treatment lines
N (%)
1
76 (70,3)
2
23 (21,2)
3
7 (6,48)
4
1 (0,92)
5
1 (0,92)
Table 2. Drugs used in patients with ET.
Treatment
N
Hydroxiurea
99
Anagrelide
31
Interferon
10
Busulfan
4
Melphalan
1
Danazol
1
Table 3. Current treatment of ET patients
Current treatment
N
No treatment
34 (29 never treated, 5 no currently)
in treatment
108
Hydroxyurea
76
Anagrelide
22
INF
6
Busulfan
1
Danazol
1
Hydroxyurea + Anagrelide
2

Conclusion
This study highlights that, although ET has a very good prognosis, there is a significant percentage of patients that will need a change of treatment, either because of resistence or intolerance.

Session topic: 16. Myeloproliferative neoplasms - Clinical

Keyword(s): Treatment, Essential Thrombocytemia

Premium Sponsors

What's new at EHA

Browse the open-source material from EHA past Congresses and meetings.

References

EHA Terms & Conditions
2025 ©
European Hematology Association
USER TERMS AND CONDITIONS / PRIVACY POLICY
(Amended according to GDPR)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies